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–1.03  8 1.44 to 2.77  8 1.95; p = 0.001), height SDS (from 
–2.41  8 0.71 to –1.81  8 0.87; p  ! 0.001), and IGF-1 values 
(from –0.57  8 1.23 to 0.63  8 1.63 SDS, p = 0.010) without 
affecting body mass index SDS. Height SDS measured at the 
last visit was significantly correlated with chronological age 
(r = –0.618, p = 0.032), bone age (r = –0.582, p = 0.047) and 
height SDS (r = 0.938, p  ! 0.001) at the beginning of treat-
ment. No adverse events were reported on rhGH therapy 
which was never discontinued.  Conclusion: These data 
showed that impaired GH secretion is not uncommon in 
SHOX deficiency subjects, and that rhGH therapy may be 
effective in increasing height in most of these patients inde-
pendent of their GH secretory status, without causing any 
adverse events of concern.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Longitudinal growth and final height are the results of 
multifactorial processes regulated by endocrine factors 
and intrinsic systems of the skeletal bones modulating 
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 Abstract 
 Background/Aims: Mutations of the short stature homeo-
box-containing  (SHOX) gene on the pseudoautosomal re-
gion of the sex chromosomes cause short stature. GH treat-
ment has been recently proposed to improve height in 
short patients with SHOX deficiency. The aim of this study 
was to evaluate GH secretion and analyze growth and safe-
ty of recombinant human GH (rhGH) therapy in short chil-
dren and adolescents with SHOX deficiency.  Patients and 
Design: We studied 16 patients (10 females; 9.7  8 2.9 years 
old; height –2.46  8 0.82 standard deviation score, SDS) with 
SHOX deficiency. All subjects underwent auxological evalu-
ations, biochemical investigations, and were treated with 
rhGH  (0.273  8 0.053 mg/kg/week).  Results: Impaired GH 
secretion was present in 37.5% of the studied subjects. Com-
paring baseline data with those at the last visit, we found 
that rhGH treatment improved growth velocity SDS (from 
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the balance of proliferation and differentiation of chon-
drocytes for normal bone extension in length and width. 
In recent years, several studies evaluated the role of 
the short stature homeobox-containing  (SHOX) gene on 
bone growth to explain some cases of growth failure as-
sociated with bone dysmorphology  [1] .
 The  SHOX gene is located on the short arms of both 
sex chromosomes inside the telomeric part of the pseu-
doautosomal region 1 (PAR1) at Xp22.3. It encodes two 
transcripts called SHOXa and SHOXb that are generated 
by alternative splicing of its 3  exons. Both SHOXa and 
SHOXb are nuclear proteins acting as transcriptional fac-
tors and, probably, SHOXb transcripts act as transcrip-
tional modulators of SHOXa  [2] . The proteins seem to be 
specifically expressed in the growth plate in hypertrophic 
chondrocytes undergoing apoptosis, and they appear to 
play an important role in the regulation of chondrocyte 
differentiation and proliferation  [3] .
 SHOX gene function is dosage dependent; therefore, 
the loss of function of one SHOX allele (haploinsufficien-
cy) results in SHOX deficiency. The most frequent  SHOX 
mutations can encompass the  SHOX gene itself  [4] or the 
regulatory enhancer regions downstream  [5] or upstream 
of the SHOX gene  [6] . These deletions account for around 
80% of all mutations. Until now, 224 unique allelic vari-
ants have been reported in the SHOX database (http://
www.hd-lovd.uni-hd.de).
 Haploinsufficiency of the  SHOX gene was demonstrat-
ed to be causative in Leri-Weill dyschondrosteosis (LWD; 
OMIM 127300), a mesomelic dysplasia characterized by 
short stature associated with short lower legs and Made-
lung deformity of the forearms  [7, 8] . Turner syndrome 
(TS) is also associated with the loss of one  SHOX gene 
because of the numerical or structural aberration of the 
X chromosome; so, SHOX deficiency may account for the 
short stature as well as some of the limb skeletal anoma-
lies  [9–11] .
 In many children before the age of 6 years, the charac-
teristic signs of LWD cannot be easily detectable in spite 
of a careful clinical evaluation; thus, the phenotype re-
sembles the typical presentation of idiopathic short stat-
ure (OMIM 300582), defined by a height below –2 stan-
dard deviation score (SDS) without any known specific 
causative disorders.
 A positive response to recombinant human GH (rhGH) 
therapy was clearly shown in patients with TS  [12] , and 
subsequently was proposed for short stature due to iso-
lated SHOX deficiency. However, up to now the data of 
only few patients treated with GH have been reported in 
the literature  [13–15] . Moreover, there are few reports in-
vestigating the frequency of altered GH secretion in sub-
jects with SHOX deficiency.
 The aim of this study was to evaluate the prevalence of 
impaired GH secretion in patients with genetically con-
firmed SHOX deficiency and the effect of rhGH on their 
growth.
 Subjects and Methods 
 Clinical and Biochemical Assessment 
 Sixteen children and adolescents (6 males) with genetically 
confirmed SHOX deficiency were included in the study; they were 
recruited from the Pediatric Endocrinology Units of the Universi-
ties of Modena and Reggio Emilia, Turin, Bologna, Pisa, Parma, 
Bolzano, Genoa, and Palermo. The Ethical Committee at the co-
ordinating center at the University of Modena and Reggio Emilia 
approved the study, and written informed consent was obtained 
from all patients’ and parents for data collection at the moment of 
the study.
 All patients underwent a complete clinical history and physi-
cal examination including anthropometric measurements that 
were performed by well-trained examiners according to the An-
thropometric Standardization Reference Manual  [16] . Height was 
measured to the nearest 0.1 cm using a wall-mounted stadiometer 
(Harpenden, Crymych, UK). Body weight was measured to the 
nearest 0.1 kg, and body mass index (BMI) was calculated as 
weight in kg/height in meters squared and expressed as z score 
with respect to chronological age using national growth charts 
 [17] .
 Pubertal development was determined using the grading sys-
tem defined by Tanner for breast (B) and genital stage (G) accord-
ing to gender  [18] .
 The patients were submitted to endocrinological investiga-
tions with the measurement of basal serum GH, IGF-1, IGFBP-3, 
T 4 , and TSH concentrations. Moreover, arginine (0.5 g/kg intra-
venously) and/or  L -dopa (500   g/1.73 m 2 orally) and/or clonidine 
(100   g/m 2 , max. 150   g, orally) tests were performed in different 
days to evaluate GH secretion. The second GH stimulation test 
was performed only in subjects that had a poor GH response at 
the first stimulation.
 Altered GH secretion was defined based on the classical auxo-
logical criteria and on a poor GH response ( ! 10   g/l) to two stim-
ulation tests. Considering both chronological age and pubertal 
stage of each single patient, priming with sex steroids before GH 
stimulation test was not considered necessary for identification of 
impaired GH secretion in this series.
 Hormonal concentrations were determined using specific 
commercially available kits. GH was assayed using an IRMA as-
say (DIAsource ImmunoAssays SA, Louvain-la-Neuve, Belgium). 
The intra-assay coefficient of variation (CV) was 2.7%, and the 
interassay CV was 7.2%. IGF-1 was measured using an IRMA 
method (DSL-5600, Diagnostic System Laboratories Inc., Web-
ster, Tex., USA). The intra-assay CV was 2.6%, and the interassay 
CV was 4.4%. Prior to assaying, IGFBPs were precipitated by acid-
ethanol extraction. IGFBP-3 was measured using an IRMA meth-
od (Diagnostic System Laboratories). The intra-assay CV was 
2.9% and the interassay CV 1%.
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 In all subjects, skeletal maturation was assessed on the basis of 
roentgenograms of the left hand and wrist. Bone age was deter-
mined according to the method of Greulich and Pyle  [19] .
 Molecular/Genetic Analyses for SHOX Gene Defects 
 Genomic DNA was extracted from peripheral blood sample by 
standard methods after  patients and/or parents signed an in-
formed consent form. Genetic analysis was performed as previ-
ously described  [20] and briefly summarized below.
 Multiplex ligation-dependent probe amplification (MLPA) 
analysis – The sample was screened for the presence of deletions 
or duplications within the  SHOX gene and the PAR1 region by 
MLPA using the SHOX salsa P018B kit (MRC-Holland, Amster-
dam, The Netherlands) according to manufacturer’s protocol.
 Microsatellite Analysis  
 Microsatellite analysis was performed using the following loci: 
CA SHOX and DXYS10092, respectively, 15 and 3.5 kb upstream 
of SHOX, the intragenic DXS10150, DYS290 and DXYS10093, and 
DXS10149, DXYS233 and DXYS234, respectively 192 kb, 280 kb 
and 1.1 Mb downstream of SHOX. The microsatellites DXS10149 
and DXYS233 encompass an 86-kb region including SHOX en-
hancer. Amplifications were performed in a reaction volume of 25 
  l containing 1 ! EuroTaq buffer, 1.5 m M MgCl 2 , 1.25 U EuroTaq 
polymerase (EuroClone, Siziano, Italy) 100 ng genomic DNA, 10 
pmol fluorescently labeled forward primer, 10 pmol unlabeled re-
verse primer and 200   M dNTPs. Amplification products were 
diluted and separated by electrophoretic run on the 3100-Avant 
genetic analyzer automatic sequencer (Applied Biosystems, Fos-
ter City, Calif., USA). Allele sizes were determined in relation to 
internal size standards (Genescan 500 Rox) by use of Genescan 
3.7 (Applied Biosystems).
 Sequence Analysis  
 Point mutations and small deletions and insertions in SHOX 
coding sequences and intron/exon boundaries (that could ac-
count for the phenotype) were investigated by direct sequencing 
of all the coding exons of the gene isoform A (from exon 2 to exon 
6a). PCR amplifications of exons were performed in 25   l reaction 
volume containing 1 ! EuroTaq buffer, 1.5 m M MgCl 2 , 1.25 U
EuroTaq polymerase (EuroClone), 200 ng genomic DNA, 15 pmol 
of each primer and 200   M dNTPs. PCR amplicons were con-
trolled on agarose gel, cleaned up using ExoSAP-IT (USB, Staufen, 
Germany) and sequenced directly in the forward and reverse di-
rections. PCR fragments were sequenced using the same PCR am-
plification primers. Sequencing was performed using ABI Prism 
BigDye terminator V3.1 (Applied Biosystems) sequencing chem-
istry and isopropanol precipitation. Reactions were run on ABI 
3100 capillary sequencer (Applied Biosystems) according to the 
manufacturer’s instructions, and sequence electropherograms 
analyzed by Seqscape V2.0 (Applied Biosystems).
 GH Treatment 
 All patients were submitted to rhGH treatment according to 
the Italian Agency for Drugs (AIFA) guidelines, at the mean dose 
of 0.273 mg/kg/week by daily SC injections, for at least 1 year.
 Statistical Analysis 
 All results are presented as mean  8 SD. The statistical analy-
sis (STATISTICA, StatSoft Inc., Tulsa, Okla., USA) was performed 
using the Student’s t test for paired samples, Student’s t test for 
unpaired samples and ANOVA to locate significant differences in 
average values of height (cm and SDS), growth velocity (cm and 
SDS), height corrected for target height SDS (TH SDS)  [21] , BMI 
(kg/m 2 and SDS), bone age, and IGF-1 (ng/ml and SDS) when ap-
propriate. Pearson’s correlation was also performed to assess the 
presence of relationship between the variables. A p value  ! 0.05 
was considered significant.
 Results 
 Baseline Data 
 Baseline height was –2.46  8 0.82 SDS (range from 
–4.30 to –1.50 SDS) and growth velocity was –1.08  8 1.36 
SDS (range from –2.81 to 1.66 SDS). The TH was –1.38  8 
0.93 SDS, and children’s height SDS correct for TH SDS 
was –1.08  8 0.77. BMI SDS was 0.16  8 0.97. Bone age was 
8.99  8 3.11 years with a delay with respect to chrono-
logical age of –0.76  8 0.87 years. Mean IGF-1 levels were 
229.8  8 171.9 ng/ml, being below the normal range in 4 
patients. IGF-1 SDS values were on average in the low-
normal range (–0.80  8 1.28 SDS) despite the differences 
between the values of individual subjects (range from 
–3.01 to 1.22 SDS). The prevalence of females was 62.5% 
(10 out 16). No significant differences were found for 
height SDS and BMI SDS between males and females. 
Eight subjects (5 females) were prepubertal.
 Details on phenotype and genotype characteristics are 
provided in  table 1 . Phenotypical findings were sugges-
tive for LWD in 10 cases and for idiopathic short stature 
in 5 cases. In one case, SHOX deficiency was demonstrat-
ed in a patient who also had trichorhinophalangeal syn-
drome. Molecular analysis showed a mutation/deletion of 
the  SHOX gene in all subjects. In 10 subjects, we showed 
minute or large deletions, while in 6 patients, we found a 
mutation. The same genetic alterations were demonstrat-
ed in 8 families (5 in fathers); in 7 families no mutations 
were detected, while in one family, parents did not con-
sent to be tested for.
 Thyroid function was normal in all subjects.
 The first GH stimulation test showed a blunted GH 
response in 7 out 16 subjects, and the second stimulation 
test allowed us to make the diagnosis of impaired GH se-
cretion in 6 subjects (37.5%).
 Response to rhGH Treatment 
 All our patients were treated with rhGH according to 
AIFA guidelines, but at the end of the study, 13 out 16 had 
completed at least 1-year follow-up (2.31  8 1.59; range 
1.00–6.40). The following data, thus, are referred only to 
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these subjects ( table 2 ) excluding the 10-year-old girl with 
trichorhinophalangeal syndrome whose growth data will 
be described separately.
 Growth velocity and height SDS improved in response 
to rhGH therapy from baseline to the last visit. In detail, 
rhGH treatment improved growth velocity SDS (–1.03  8 
1.44 vs. 2.77  8 1.95, respectively; p  ! 0.001), height SDS 
(–2.41  8 0.71 vs. –1.81  8 0.87, respectively; p  ! 0.001; 
 fig. 1 a) and height SDS correct for TH (–1.13  8 0.86 vs. 
–0.53  8 0.73, respectively; p  ! 0.001). The change of the 
height SDS of each treated subject is shown in  figure 1 b. 
The main significant gains in growth velocity SDS and 
height SDS were observed during the first year of rhGH 
treatment ( table 2 ). BMI SDS was unchanged (0.06  8 1.09 
vs. 0.01  8 0.84, respectively; p = 0.815). At the last visit, 
the gain in height SDS (  ) was 0.60  8 0.32.
 A significant difference was detected between TH SDS 
and basal height SDS (–1.28  8 0.91 vs. –2.41  8 0.71, re-
spectively; p = 0.003), while no significant difference was 
found with the last measured height SDS ( fig. 1 a).
 Only the patient with SHOX deficiency and trichorhi-
nophalangeal syndrome failed to improve height SDS on 
GH treatment considering that after 2.5 years of therapy 
her height decreased from –1.50 to –2.47 SDS ( fig. 1 b, pa-
tient 11) with a growth velocity of –4.11 SDS.
 In the rhGH-treated SHOX deficiency subjects, bone 
age delay changed significantly from baseline to the last 
visit (0.65  8 0.78 vs. 0.22  8 0.70 years’ delay; p = 0.042; 
 table 2 ), in particular in the GH deficiency (GHD) pa-
tients who had not yet entered puberty at the beginning 
of rhGH therapy.
 IGF-1 SDS values significantly increased to the upper-
normal range during rhGH treatment (from –0.57  8 
1.23 to 0.63  8 1.63, p = 0.010). During rhGH treatment, 
IGF-1 concentrations exceeded +2 SDS at the last evalua-
tion in 2 subjects, both with normal GH responses to 
stimulation tests.
 Correlation Analysis 
 Height SDS measured during the last visit was inverse-
ly correlated with both baseline chronological age (r = 
–0.618, p = 0.032;  fig. 2 a) and bone age (r = –0.582, p = 
0.047), while no significant correlation was found with 
baseline bone age delay (r = –0.007, p = 0.983;  fig. 2 b). 
Analyzing data using   height SDS, we found a signifi-
cant correlation with bone age at baseline (r = –0.656,
p = 0.020) but not with chronological age (r = –0.534, p = 
0.732). A significant positive correlation was also found 
between height SDS before the beginning of the treat-
ment and at the last visit (r = 0.938, p  ! 0.001). The best 
catch-up growth was obtained in the 3 younger patients, 
one of whom was affected by impaired GH secretion.
 Considering data after 1st-year rhGH therapy, signifi-
cant correlations were only found between   height SDS 
with both baseline chronological age (r = –0.855, p  ! 
0.001;  fig. 2 c) and bone age (r = –0.911, p  ! 0.001).
Table 1. P henotype and genotype characteristics of each studied case
Case Gender Age, years Genotype Phenotype Height (SDS) GH peak, ng/ml
1 M 14.5 deletion (465C) short stature; Madelung deformity –3.80 21.0
2 F 12.0 deletion short stature; dyschondrosteosis –3.00 21.2
3 F 5.6 deletion short stature –2.40 28.7
4 F 11.4 deletion short stature –2.20 17.6
5 M 4.9 mutation short stature –2.30 19.5
6 M 8.5 deletion short stature –2.00  7.49
7 M 9.0 mutation promoter short stature; Madelung deformity –2.10  6.30
8 F 8.1 deletion short stature; Madelung deformity –2.02 12.8
9 F 6.3 deletion short stature –1.68  7.80
10 F 11.5 deletion short stature; Madelung deformity –1.80  7.00
11 F 10.0 mutation
trichorhinophalangeal syndrome
short stature; Madelung deformity
trichorhinophalangeal syndrome –1.50  7.00
12 M 13.2 deletion short stature; Madelung deformity –1.92  9.20
13 F 12.4 mutation short stature; Madelung deformity –3.71 24.9
14 M 10.6 deletion short stature; Madelung deformity –2.10 13.1
15 F 6.2 mutation short stature; Madelung deformity –2.60 11.0
16 F 11.9 mutation short stature; Madelung deformity –4.30 37.3
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 Subgroup Analyses 
 Subjects without GHD had significantly lower base-
line height SDS (–2.77  8 0.73 vs. –1.90  8 0.16 SDS, re-
spectively; p = 0.027) and BMI SDS with respect to the 
ones with impaired GH secretion (–0.36  8 1.10 vs. 0.95 
 8 0.59 SDS, respectively; p = 0.036). Age and bone age 
were comparable, and no significant difference between 
groups was detected ( table 2 ).
 The 5 patients with impaired GH secretion and the 7 
with normal GH secretion were treated with a compara-
ble GH dosage, and showed a significant response to the 
rhGH. Specifically,   height SDS in subjects with GHD 
and without GHD were 0.66  8 0.27 and 0.55  8 0.36, re-
spectively (NS). Moreover, patients with impaired GH 
production had a significant increase in IGF-1 levels that 
was not found in the other group ( table 2 ).
 Safety 
 During rhGH therapy, no discontinuation due to ad-
verse events was found, and no adverse event of concern 
was reported. Moreover, Madelung deformity that was 
present in 6 out 12 at the start of therapy did not deterio-
rate during follow-up.
 Discussion 
 Patients with mutations or deletions of the  SHOX gene 
have variable degrees of growth impairment, with or 
without evident mesomelic skeletal dysplasia. Growth 
failure starts early during the first years of life, and the 
mean final height is around 2 SDS below the mean. How-
ever, longitudinal follow-up studies of children carrying 
Table 2. Clinical and laboratory data at baseline and last visit during rhGH therapy of S HOX deficiency patients
All cases GHD N o GHD
baseline last visit baseline last visit ba seline last visit
Chronological age, years 9.7883.16 12.183.96* 9.7082.69 13.183.90* 9.8483.66 11.384.12*
Sex, male/female 5/7 3/2 2/5
Puberty, yes/no 8/4 9/3 4/1 5/0 4/3 4/3
Bone age, years 8.9283.44 11.784.58* 9.3082.77 13.484.26* 9.0183.94 10.284.66*
Bone age delay, years
(bone age – chronological age) –0.6580.78 –0.2280.70* –0.4080.67 0.3080.47 –0.8380.86 –0.6080.61
Madelung deformity, yes/no 6/6 3/2 3/4
Height, cm 121.8815.3 136.6819.6* 123.5813.7 145.1820.3* 120.5817.3 130.6818.1*
Height, SDS –2.4180.71 –1.8180.87* –1.908 0.16 –1.2480.33* –2.7780.73# –2.2280.91*
TH, SDS –1.2880.91 –1.1880.77 –1.3580.52
Height, SDS correct for TH –1.1380.86 –0.5380.73* –0.7280.64 –0.1480.67* –1.4280.90 –0.8180.67*
Final height, SDS   0.6080.32    0.6680.27   0.5580.36
BMI 17.382.52 18.283.22 18.781.97 18.781.12 16.983.18 17.984.04
BMI, SDS 0.0681.09 0.0180.84 0.9580.59 0.3280.66 –0.3681.10# –0.1680.92
Growth velocity, SDS 1.0381.44 2.7781.95* –1.7280.64 2.8782.62* –0.7381.51 3.7281.60*
1st year
Height, SDS
Height, SDS
Growth velocity, SDS
Growth velocity, SDS
  –1.9880.91*
0.4380.33
2.5081.76*
3.5382.18
  –1.5080.32*
0.4080.24
3.3681.10*
5.0881.50
  –2.3281.06*
0.4580.40
2.0881.95*
2.7782.13
Max GH peak value, ng/ml
Median
Q1
Q3
15.387.82
15.2
7.64
21.1
7.5581.07
7.49
7.00
7.80
20.885.08*
21.0
17.6
24.9
IGF-1, ng/ml 229.08212.8 405.48294.6* 162.5890.0 384.3874.6* 307.18219.6 418.18385.5
IGF-1, SDS –0.5781.23 0.6381.63* –1.0980.61 0.7481.35* –0.3781.35 0.5781.93 
rhGH, mg/kg/week   0.27180.058   0.27580.028   0.26880.075
rhGH duration, years 2.3081.66 3.2881.87 1.4880.64
* p < 0.05, intragroup (vs. baseline); # p < 0.05, intergroup (vs. the same time).
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 SHOX defects suggest a relatively well-preserved prepu-
bertal growth followed by compromised pubertal growth 
due to premature growth plate fusion, thus causing pre-
mature growth arrest  [22] . This raises concerns regarding 
the adult height prognosis of these ‘normal’ height chil-
dren with SHOX deficiency which, if untreated, gener-
ally remain short in adulthood.
 An insufficient GH secretion was previously described 
in 3 subjects with  SHOX mutation; however, IGF-1 and 
IGFBP-3 serum levels were in the normal range, so the 
authors concluded that classical GHD was not present in 
these children  [13] . Subnormal GH response was also re-
ported in 5 children with LWS  [23] . Recently, Urakami et 
al.  [24] reported that 2 sisters with SHOX deficiency had 
normal peak GH levels after stimulation test.
 All our SHOX deficiency subjects were submitted to 
GH stimulation test: a blunted GH response was demon-
strated in 6 out of 16 subjects. Moreover, mean IGF-1 SDS 
values were on average in the low-normal range. This 
study demonstrated that SHOX deficiency was not un-
commonly associated with impaired GH secretion which 
was in fact detected in about 40% of our subjects.
 The indication for the use of rhGH in children without 
classical GHD has been widened over years to diseases 
such as TS, chronic renal failure, being born small for 
gestational age and Prader-Willi syndrome. The rationale 
for rhGH therapy in these conditions relates to the strong 
dose-dependent growth-promoting effect of GH. The ef-
fect of rhGH is associated with the induction of the same 
intracellular signaling response triggered by endogenous 
GH and, in most cases, with increased serum concentra-
tions of the GH-dependent peptides IGF-1 and IGFBP-3. 
Apart from intrinsic individual variations in responsive-
ness, the magnitude of the growth response to rhGH de-
pends on other external factors, including frequency of 
administration, concomitant replacement of other hor-
mones, nutritional status, age at treatment initiation, 
dose, and duration of treatment.
 Until now, there have been reports on only about 50 
subjects with SHOX deficiency treated with rhGH  [25] . 
The first reports on the treatment of SHOX deficiency 
patients with rhGH did not provide a definite response 
on the efficacy of this treatment, showing controversial 
results. Two siblings with a  SHOX point mutation were 
reported to respond well to rhGH therapy (0.33 mg/kg/
week)  [13] . Shanske et al.  [26] and Munns et al.  [27] also 
described a similar effect after 1 year on rhGH therapy 
(0.21 and 0.28 mg/kg/week, respectively), reporting a sig-
nificant improvement in height SDS and growth velocity. 
These first case reports suggested that high-dose rhGH 
therapy was effective in short patients with SHOX defi-
ciency, but a recent case report showed that low-dose 
rhGH therapy (0.175 mg/kg per week) was also effective 
in 2 young sisters  [24] . In a randomized multicenter trial, 
subjects with genetically proven SHOX deficiency were 
reported to have significant growth improvement during 
a 2-year rhGH treatment period. Specifically, in the treat-
ed group growth velocity was 8.7 cm/year during the 1st 
year and 7.3 cm/year during the 2nd year, both signifi-
cantly higher compared with growth velocity before 
treatment. In addition, a recent study by the same group 
concluded that patients with SHOX deficiency achieved 
comparable final height from rhGH therapy as those with 
TS. More recently, it was reported that 16 children treated 
with rhGH had an increase in height from –2.7  8 0.7 to 
–1.4  8 0.7 SDS. Some studied children achieved adult 
height (–2.0  8 0.9 SDS) with a gain over baseline height 
of 1.0  8 0.5 SDS after a mean treatment duration of 5.8 
 8 2.1 years  [28] . In general, rhGH therapy is sufficiently 
beneficial in improving height in most cases of TS and 
SHOX deficiency  [14, 15, 29] .
 Our data confirm that growth velocity in subjects 
with SHOX deficiency is significantly accelerated during 
rhGH therapy, and suggest that treatment can result in a 
significant gain in height, taking TH also into consider-
ation. In detail, 12 out of 13 subjects improved their 
growth rate on rhGH treatment, and this resulted in a 
progressive increase in height SDS; only the patient with 
SHOX deficiency and trichorhinophalangeal syndrome 
failed to improve height SDS during hormonal treat-
ment.
 Moreover, one must consider that the lack of a signifi-
cant difference between the children’s heights and THs at 
the last visit could be ascribed also to the effect of their 
genetic background (short parents having SHOX defi-
ciency). This represents a limit of the study which, how-
ever, cannot be overcome.
 The SHOX deficiency patients with normal GH secre-
tion showed the same response to rhGH treatment as 
those with impaired GH secretion. However, as a bias of 
our study, we must point out that because of the different 
duration of rhGH treatment between subjects with im-
paired and normal GH secretion, growth response vari-
ables at the last visit cannot be directly compared. Inter-
estingly, in the subjects with impaired GH secretion, 
baseline height SDS was higher than in those with normal 
GH secretion. This finding could be partially explained 
by the early identification of altered GH secretion and 
subsequently of SHOX deficiency according to the knowl-
edge developed during recent years which forced us to 
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include  SHOX gene analysis in the workup of short pa-
tients without impaired GH secretion.
 Treatment response was similar between males and fe-
males. With respect to previous published studies, the 
lower gain in height SDS we found in our SHOX-deficient 
patients may reflect a delay in starting rhGH treatment 
(mean age 9.8 years) and the low mean rhGH dose (0.27 
mg/kg/week) used.
 It is well known that prepubertal height is an impor-
tant predictor of adult height, and Davenport et al.  [30] 
demonstrated that starting rhGH early in children with 
TS not only prevented further worsening of height SDS 
but normalized height after 2 years of treatment. Our 
study supported, at least in part, these data considering 
that height SDS measured at the last visit was inversely 
correlated with both baseline chronological age and bone 
age; moreover, a significant positive correlation was 
found with height SDS before the beginning of the treat-
ment. Furthermore, the best catch-up growth was ob-
tained in the 3 younger patients, independent of GHD.
 The mechanism by which  SHOX regulates linear 
growth and why its deficiency results in short stature is 
not completely understood. In vitro experiments suggest 
an antiproliferative effect of  SHOX  [1, 3] .
 Based on the evidence that rhGH treatment induced 
catch-up growth in short patients with SHOX deficiency 
 [14] and resulted in gain in final height SDS, which would 
probably not be attained spontaneously, the height gain 
in these treated patients could be likely due to a direct 
treatment effect of rhGH. Considering the relatively low 
baseline IGF-1 concentrations in our subjects, one could 
also speculate that  SHOX may be involved in the regula-
tion of the IGF-1 gene. Furthermore, IGF-1 levels re-
sponded well to rhGH therapy, supporting further the 
hypothesis that there is no evidence of GH resistance or 
insensitivity  [14] .
 Subjects with SHOX deficiency generally undergo 
normal pubertal development with appropriate bone age 
progression. We cannot discuss the contribution of estro-
gen/testosterone to skeletal maturation. Studies in chil-
dren with SHOX deficiency demonstrated a near-normal 
prepubertal growth rate, with a more affected pubertal 
growth due to premature growth plate fusion suggesting 
important effects of gonadal hormones (especially estro-
gens in females)  [20, 29] . Ogata et al.  [31] have shown that 
GnRH analog therapy associated with rhGH treatment 
before entry into puberty might be useful to prevent the 
development of skeletal lesions, and could help in the im-
provement of final height, especially in female patients 
with SHOX deficiency. More recently, Scalco et al.  [22] 
compared, in a small group of children with SHOX defi-
ciency, the adult height of a control group with the adult 
height of a group who used the combination of rhGH and 
GnRH analog with the aim of delaying the fusion of the 
growth plates. They showed that the control group had a 
height of –1.2 SDS at the beginning of puberty and an 
adult height of –2.5 SDS, whereas children in the treat-
ment group improved their height from –2.3 SDS at the 
beginning of puberty to an adult height of –1.7 SDS. It was 
not clear, however, whether rhGH alone or the combina-
tion of rhGH with GnRH analog increased further adult 
height.
 There was no evidence of any new or unexpected
rhGH-related adverse events in the SHOX deficiency
patient population in which this hormonal treatment 
showed a safety profile comparable to that reported in 
other pediatric indications for which rhGH has previous-
ly been approved  [32, 33] .
 In conclusion, our data showed that in SHOX deficien-
cy subjects an altered GH secretion is not uncommon, 
and rhGH therapy may be effective in increasing height 
in most of these patients independent of GH secretion, 
without causing adverse events of concern.
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